Diabetes case identification methods applied to electronic medical record systems: Their use in HIV-infected patients

Current HIV Research

Volumn 4, Issue 1, 2006, Pages 97-106

  Crane, Heidi M ^a   Kadane, Joseph B ^b   Crane, Paul K ^a   Kitahata, Mari M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CARNEGIE MELLON UNIVERSITY   (United States)

Author keywords

Diabetes; Electronic medical records; HIV

Indexed keywords

ACARBOSE; ANTIRETROVIRUS AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ADULT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE CLASSIFICATION; ELECTRONIC MEDICAL RECORD; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; ARTICLE; EVALUATION; MEDICAL RECORD; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION AND FORECASTING; PREVALENCE; UNITED STATES; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; SENSITIVITY AND SPECIFICITY; WASHINGTON;

EID: 33644898569     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016206775197637     Document Type: Review

References (54)

1. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine. 338:853-860.
2. Fordyce EJ, Singh TP, Nash D, Gallagher B, Forlenza S. (2002). Survival rates in NYC in the era of combination ART. Journal of Acquired immune Deficiency Syndromes. 30:111-118.
3. Paparizos VA, Kyriakis KP, Botsis C, Papastamopoulos V, Hadjivassiliou M, Stavrianeas NG. (2000). Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus. AIDS. 14:903-905.
4. Dever LL, Oruwari PA, Figueroa WE, O'Donovan CA, Eng RH. (2000). Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population. Annals of Pharmacotherapy. 34:580-584.
5. Visnegarwala F, Krause KL, Mosher DM. (1997). Severe diabetes associated with protease inhibitor therapy. Annals of Internal Medicine. 127:947.
6. Paterson DL, Singh N. (1998). Exacerbated hyperglycemia associated with nelfinavir. Annals of Pharmacotherapy. 32:609-610.
7. Meyer L, Rabaud C, Ziegler O, May T, Drouin P. (1998). Protease inhibitors, diabetes mellitus and blood lipids. Diabetes and Metabolism. 24:547-549.
8. Hardy H, Esch LD, Morse GD. (2001). Glucose disorders associated with HIV and its drug therapy. Annals of Pharmacotherapy. 35:343-351.
9. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM. (2001). Metabolic complications associated with antiretroviral therapy. Antiviral Research. 51:151-177.
10. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, MacDonald TM. (1997). The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. British Medical Journal. 315:524-528.
11. Selby JV, Karter AJ, Ackerson LM, Ferrara A, Liu J. (2001). Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. Diabetes Care. 24:1547-1555.
12. Newton KM, Wagner EH, Ramsey SD, McCulloch D, Evans R, Sandhu N, Davis C. (1999). The use of automated data to identify complications and comorbidities of diabetes: a validation study. Journal of Clinical Epidemiology. 52:199-207.
13. Engelgau MM, Geiss LS, Manninen DL, Orians CE, Wagner EH, Friedman NM, Hurley JS, Trinkaus KM, Shatin D, Van Vorst KA. (1998). Use of services by diabetes patients in managed care organizations. Development of a diabetes surveillance system. CDC Diabetes in Managed Care Work Group. Diabetes Care. 21:2062-2068.
14. Montori VM, Smith SA. (2001). Information systems in diabetes: in search of the holy grail in the era of evidence-based diabetes care. Experimental and Clinical Endocrinology and Diabetes. 109 Suppl 2:S358-372.
15. Wilson C, Susan L, Lynch A, Saria R, Peterson D. (2001). Patients with diagnosed diabetes mellitus can be accurately identified in an Indian Health Service patient registration database. Public Health Reports. 116:45-50.
16. Schambelan M, Benson CA, Carr A, Currier JS, Dube MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS. (2002). Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. Journal of Acquired Immune Deficiency Syndromes. 31:257-275.
17. Stringer JR, Beard CB, Miller RF, Wakefield AE. (2002). A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerging Infectious Diseases. 8:891-896.
18. International Classification of Diseases, 9th Revision. (2002). Los Angeles, Practice Management Information Cooperation.
19. Altman DG. (1995).Ch 14. Some Common Problems in Medical Research. In: Practical Statistics for Medical Research. New York, Chapman & Hall. pp. 397-439.
20. Pepe MS. (2003). Ch 2. Measures of Accuracy for Binary Tests. In: The Statistical Evaluation of Medical Tests for Classification and Prediction. New York City, Oxford University Press. pp. 14-34.
21. Simel DL, Samsa GP, Matchar DB. (1991). Likelihood ratios with confidence: sample size estimation for diagnostic test studies. Journal of Clinical Epidemiology. 44:763-770.
22. Schervish MJ. (1995). Theory of statistics. New York, Springer-Verlag.
23. Armstrong BK, White E, Saracci R. (2000). Principles of Exposure Measurement in Epidemiology. vol 21. Oxford. Oxford University Press.
24. Greenberg RA, Sacks DB. (2002). Screening for diabetes: is it warranted? Clinica Chimica Acta 315:61-69.
25. Roubicek M, Vines G, Gonzalez Sanguineti A. (1998). Use of HbA1c in screening for diabetes. Diabetes Care. 21:1577-1578; author reply 1578-1579.
26. Eberhardt MS, Flegal KM. (1998). Assessing the utility of glycated hemoglobin. Diabetes Care. 21:1578-1579.
27. Goldstein DE. (1998). Isn't it time to retire the oral glucose tolerance test for diabetes screening and diagnosis? Diabetes Care. 21:1215-1216.
28. Harris MI, Eastman RC. (1996). Early detection of undiagnosed non-insulin-dependent diabetes mellitus. Journal of the American Medical Association. 276:1261-1262.
29. Herman WH, Engelgau MM, Zhang Y, Brown MB. (2000). Use of GHb (HbA(1c)) to screen for undiagnosed diabetes in the U.S. population. Diabetes Care. 23:1207-1208.
30. Polgreen PM, Putz; D, Stapleton JT. (2003). Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. Clinical Infectious Diseases. 37:e53-56.
31. Puavilai G, Kheesukapan P, Chanprasertyotin S, Chantraraprasert S, Suwanvilaikorn S, Nitiyanant W, Deerochochanawong C, Benjasuratwong Y, Munsakul N, Pongchaiyaikul C, Kespechara K, Montreewasuwat N. (2001). Random capillary plasma glucose measurement in the screening of diabetes mellitus in high-risk subjects in Thailand. Diabetes Research and Clinical Practice. 51:125-131.
32. Finch CF, Dowse GK, Collins VR, Zimmet PZ. (1990). Quantifying the extent to which random plasma glucose underestimates diabetes prevalence in the Nauruan population. Diabetes Research and Clinical Practice. 10:177-182.
33. Engelgau MM, Thompson TJ, Smith PJ, Herman WH, Aubert RE, Gunter EW, Wetterhall SF, Sous ES, Ali MA. (1995). Screening for diabetes mellitus in adults. The utility of random capillary blood glucose measurements. Diabetes Care. 18:463-466.
34. Modan M, Halkin H, Karasik A, Lusky A. (1984). Effectiveness of glycosylated hemoglobin, fasting plasma glucose, and a single post load plasma glucose level in population screening for glucose intolerance. American Journal of Epidemiology. 119:431-444.
35. Rolka DB, Narayan KM, Thompson TJ, Goldman D, Lindenmayer J, Alich K, Bacall D, Benjamin EM, Lamb B, Stuart DO, Engelgau MM. (2001). Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care. 24:1899-1903.
36. Engelgau MM, Narayan KM, Herman WH. (2000). Screening for type 2 diabetes. Diabetes Care. 23:1563-1580.
37. Pepe MS. (2003).Ch 7. Incomplete Data and Imperfect Reference Tests. In: The Statistical Evaluation of Medical Tests for Classification and Prediction. New York City. Oxford University Press.
38. Walter SD, Frommer DJ, Cook RJ. (1991). The estimation of sensitivity and specificity in colorectal cancer screening methods. Cancer Detection and Prevention. 15:465-469.
39. Cecil MP, Kosinski AS, Jones MT, Taylor A, Alazraki NP, Pettigrew RI, Weintraub WS. (1996). The importance of work-up (verification) bias correction in assessing the accuracy of SPECT thallium-201 testing for the diagnosis of coronary artery disease. Journal of Clinical Epidemiology. 49:735-742.
40. Kosinski AS, Barnhart HX (2003). A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present. Statistics in Medicine. 22:2711-2721.
41. Zhou XH. (1994). Effect of verification bias on positive and negative predictive values. Statistics in Medicine. 13:1737-1745.
42. (1997). Protease inhibitors: FDA warris doctors of diabetes risk. Food and Drug Administration. AIDS Treatment News. 5-6.
43. U.S. Food and Drug Administration. (1997). Protease inhibitors may increase blood glucose in HIV patients. FDA Medical Bulletin 27.
44. Hughes CA, Taylor GD. (2001). Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis. Annals of Pharmacotherapy. 35:877-880.
45. Lee EC, Walmsley S, Fantus IG. (1999). New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. Canadian Medical Association Journal. 161:161-164.
46. Modest GA, Fuller J. (2001). Abacavir and diabetes. New England Journal of Medicine. 344:142-144.
47. Eastone JA, Decker CF. (1997). New-onset diabetes mellitus associated with use of protease inhibitor. Annals of Internal Medicine. 127:948.
48. Stausberg J, Koch D, Ingenerf J, Betzler M. (2003). Comparing paper-based with electronic patient records: lessons learned during a study on diagnosis and procedure codes. Journal of the American Medical Informatics Association. 10:470-477.
49. Parappil A, Doi SA, Al-Shoumer KA. (2002). Diagnostic criteria for diabetes revisited: making use of combined criteria. BMC Endocrine Disorders. 2:1.
50. Barr RG, Nathan DM, Meigs JB, Singer DE. (2002). Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Annals of Internal Medicine. 137:263-272.
51. Davidson MB, Schriger DL, Peters AL, Lorber B. (1999). Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria. Journal of the American Medical Association. 281:1203-1210.
52. Davidson MB, Schriger DL, Peters AL, Lorber B. (2000). Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes. Journal of General Internal Medicine. 15:551-555.
53. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. (1998). Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 21:518-524.
54. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, Grinspoon S. (2001). Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases. 32:130-139.